Insider trading

Period: 120 months Stock: ONC + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

455 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

455 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

455 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

455 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
455 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
455 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

455 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
1 Nov 2019
Wu Xiaobin President & GM China
Sold, plan not stated
$180.00K 1,000 at 180.00
100%
Sold half or more
1 Nov 2019
Wang Xiaodong Director
Sold, plan not stated
$170.00K 1,000 at 170.00
100%
Sold half or more
4 Sep 2019
Huang Jane CMO, Hematology
Sold, plan not stated
$10.61K 82 at 129.40
100%
Sold half or more
3 Sep 2019
Huang Jane CMO, Hematology
Sold, plan not stated 2×
$413.42K 2,862 at 144.45
100%
Sold half or more
23 Aug 2019
Sold, plan not stated 5×
$1.25M 8,614 at 144.96
100%
Sold half or more
12 Aug 2019
Huang Jane CMO, Hematology
Sold, plan not stated 4×
$336.85K 2,500 at 134.74
100%
Sold half or more
29 Jul 2019
Huang Jane CMO, Hematology
Sold, plan not stated 2×
$1.36M 10,130 at 134.54
100%
Sold half or more
8 Jul 2019
OYLER JOHN Chief Executive Officer
Sold, plan not stated 4×
$394.06K 3,106 at 126.87
100%
Sold half or more
1 Jul 2019
Wang Xiaodong Director
Sold, plan not stated 2×
$612.94K 4,847 at 126.46
100%
Sold half or more
27 Jun 2019
Liang Howard CFO & Chief Strategy Officer
Sold, plan not stated
$55.65K 5,876 at 9.47
4.6%
27 Jun 2019
Huang Jane CMO, Hematology
Sold, plan not stated 2×
$53.54K 430 at 124.52
100%
Sold half or more
21 May 2019
Liang Howard CFO & Chief Strategy Officer
Sold, plan not stated
$3.02M 23,200 at 130.21
100%
Sold half or more
21 May 2019
Huang Jane CMO, Hematology
Sold, plan not stated
$286.13K 2,200 at 130.06
100%
Sold half or more
20 May 2019
Huang Jane CMO, Hematology
Sold, plan not stated
$39.04K 300 at 130.12
100%
Sold half or more
13 May 2019
Glazer Donald W. Director
Sold, plan not stated
$1.88M 15,027 at 125.11
100%
Sold half or more
6 May 2019
Liang Howard CFO & Chief Strategy Officer
Sold, plan not stated
$234.01K 1,800 at 130.01
100%
Sold half or more
1 May 2019
Wu Xiaobin President & GM China
Sold, plan not stated 3×
$741.55K 5,955 at 124.52
25.5%
1 May 2019
OYLER JOHN Chief Executive Officer
Sold, plan not stated 3×
$353.50K 2,824 at 125.18
100%
Sold half or more
8 Apr 2019
Huang Jane CMO, Hematology
Sold, plan not stated 6×
$2.02M 14,130 at 142.77
100%
Sold half or more
14 Mar 2019
Glazer Donald W. Director
Sold, plan not stated
$2.04M 14,973 at 136.10
100%
Sold half or more
11 Mar 2019
Huang Jane CMO, Hematology
Sold, plan not stated
$333.45K 2,565 at 130.00
100%
Sold half or more
7 Mar 2019
Huang Jane CMO, Hematology
Sold, plan not stated
$9.98K 71 at 140.50
100%
Sold half or more
6 Mar 2019
OYLER JOHN Chief Executive Officer · indirect
Sold, plan not stated
$15.00K 100 at 150.00
50.0%
Sold half or more
5 Mar 2019
OYLER JOHN Chief Executive Officer · indirect
Sold, plan not stated 5×
$945.45K 6,230 at 151.76
100%
Sold half or more
5 Mar 2019
OYLER JOHN Chief Executive Officer
Sold, plan not stated 3×
$729.43K 4,791 at 152.25
100%
Sold half or more
4 Mar 2019
OYLER JOHN Chief Executive Officer · indirect
Sold, plan not stated 4×
$1.48M 9,790 at 151.34
100%
Sold half or more
4 Mar 2019
OYLER JOHN Chief Executive Officer
Sold, plan not stated 4×
$697.43K 4,588 at 152.01
100%
Sold half or more
1 Mar 2019
Wang Xiaodong Director · indirect
Sold, plan not stated 9×
$584.12K 4,000 at 146.03
100%
Sold half or more
1 Mar 2019
Wang Xiaodong Director
Sold, plan not stated
$150.00K 1,000 at 150.00
100%
Sold half or more
18 Dec 2018
Peterson Amy C. CMO, Immuno-oncology
Sold, plan not stated 5×
$1.36M 10,141 at 133.75
100%
Sold half or more
17 Dec 2018
Peterson Amy C. CMO, Immuno-oncology
Sold, plan not stated 7×
$1.32M 9,859 at 133.61
100%
Sold half or more
10 Dec 2018
OYLER JOHN Chief Executive Officer · indirect
Sold, plan not stated 5×
$561.86K 4,138 at 135.78
100%
Sold half or more
3 Dec 2018
Wang Xiaodong Director
Sold, plan not stated 8×
$762.06K 5,000 at 152.41
100%
Sold half or more
28 Nov 2018
OYLER JOHN Chief Executive Officer · indirect
Sold, plan not stated 7×
$1.30M 8,865 at 147.19
68.2%
Sold half or more
27 Nov 2018
OYLER JOHN Chief Executive Officer · indirect
Sold, plan not stated 7×
$1.63M 11,252 at 144.57
46.4%
26 Nov 2018
OYLER JOHN Chief Executive Officer · indirect
Sold, plan not stated 7×
$1.26M 9,078 at 139.06
27.2%
26 Nov 2018
Huang Jane CMO, Hematology
Sold, plan not stated
$418.75K 3,000 at 139.58
100%
Sold half or more
19 Nov 2018
Wang Xiaodong Director
Sold, plan not stated 5×
$621.49K 5,000 at 124.30
100%
Sold half or more
12 Nov 2018
Peterson Amy C. CMO, Immuno-oncology
Sold, plan not stated 8×
$1.36M 12,067 at 112.73
100%
Sold half or more
9 Nov 2018
Peterson Amy C. CMO, Immuno-oncology
Sold, plan not stated 7×
$1.59M 13,222 at 120.49
100%
Sold half or more
8 Nov 2018
Peterson Amy C. CMO, Immuno-oncology
Sold, plan not stated 5×
$1.85M 14,711 at 126.07
100%
Sold half or more
4 Sep 2018
Huang Jane CMO, Hematology
Sold, plan not stated
$508.25K 2,911 at 174.60
100%
Sold half or more
30 Aug 2018
Glazer Donald W. Director
Sold, plan not stated
$179.00K 1,000 at 179.00
7.0%
29 Aug 2018
Glazer Donald W. Director
Sold, plan not stated
$179.00K 1,000 at 179.00
6.5%
23 Aug 2018
Peterson Amy C. CMO, Immuno-oncology
Sold, plan not stated 4×
$975.67K 5,769 at 169.12
100%
Sold half or more
13 Aug 2018
Wang Xiaodong Director
Sold, plan not stated 3×
$547.59K 3,449 at 158.77
100%
Sold half or more
2 Aug 2018
BAKER BROS. ADVISORS LP Director · indirect
Bought 2×
$627.92M 5,814,100 at 108.00
opened
First buy on file
16 Jul 2018
OYLER JOHN Chief Executive Officer
Sold, plan not stated
$418.50K 2,550 at 164.12
100%
Sold half or more
19 Mar 2018
Liang Howard CFO & Chief Strategy Officer
Sold, plan not stated 7×
$4.70M 29,128 at 161.46
100%
Sold half or more
16 Mar 2018
Liang Howard CFO & Chief Strategy Officer
Sold, plan not stated 4×
$1.71M 10,872 at 157.07
68.5%
Sold half or more
Showing 351–400 of 455. ← Newer Page 8 of 10 Older →